Illustration of lung cancer cells with PD-L1 markers.

Lung Cancer Breakthrough: Personalized Treatment Paths with PD-L1 Testing

Jordan Keane in Health & Wellness December 2025 • 4 min read.

"New research highlights the importance of PD-L1 testing in tailoring lung cancer treatments, offering hope for more effective and personalized care."

Lung cancer remains a leading cause of cancer-related deaths worldwide, but advancements in understanding its complex biology are paving the way for more personalized and effective treatments. Among these advancements, the identification and targeting of specific molecular markers, such as Programmed Death-Ligand 1 (PD-L1), have emerged as critical strategies.

PD-L1 is a protein that helps cancer cells evade the immune system. By binding to the PD-1 receptor on immune cells, PD-L1 inhibits their ability to attack and destroy cancer cells. Immunotherapies that block this interaction have shown remarkable success in treating various cancers, including non-small cell lung cancer (NSCLC). However, not all patients respond to these therapies, making it essential to identify those who are most likely to benefit.

Recent research underscores the significance of assessing PD-L1 expression in lung cancer cells to guide treatment decisions. These studies delve into the reliability and validity of PD-L1 testing methods, compare results across different types of tissue samples, and explore innovative approaches to evaluate surgical margins. The findings aim to refine patient selection criteria and improve outcomes in lung cancer therapy.

Why PD-L1 Testing Matters in Lung Cancer Treatment

Illustration of lung cancer cells with PD-L1 markers.

PD-L1 testing is revolutionizing lung cancer treatment by enabling doctors to tailor therapies to individual patients. These tests measure the amount of PD-L1 protein on cancer cells, helping predict how likely a patient is to respond to immunotherapy. The higher the PD-L1 expression, the more likely immunotherapy will be effective.

Traditionally, PD-L1 testing has been performed on tissue samples obtained through biopsies or surgical resections. However, recent studies have explored the use of cytology specimens, which are collected through less invasive methods like fine needle aspirations or pleural effusions. Cytology offers a convenient alternative, particularly for patients who may not be able to undergo more invasive procedures.

Accuracy and Reliability: Research indicates that PD-L1 testing on cytology samples provides reliable results, comparable to those obtained from tissue samples. This is crucial for ensuring that treatment decisions are based on accurate information.
Comprehensive Assessment: Studies have assessed the performance of different PD-L1 immunohistochemistry (IHC) kits, such as 28-8 and SP263, to determine their agreement in evaluating cytology specimens. Good agreement between kits ensures consistency in PD-L1 assessment.
Interobserver Agreement: The evaluation of PD-L1 expression in cytology specimens has shown good to excellent interobserver agreement, meaning that different pathologists interpreting the same samples arrive at similar conclusions. This is vital for the reproducibility of PD-L1 testing in clinical practice.

The ability to reliably assess PD-L1 expression in cytology specimens expands the accessibility of personalized lung cancer treatment. It allows more patients to be considered for immunotherapy, potentially improving their outcomes and quality of life. As research continues to validate these findings, PD-L1 testing is poised to become an even more integral part of lung cancer management.

The Future of Lung Cancer Treatment: Personalized and Precise

As our understanding of lung cancer biology deepens, personalized approaches like PD-L1 testing are becoming increasingly important. By tailoring treatments to individual patients, we can improve outcomes, reduce side effects, and enhance the quality of life for those affected by this disease. The ongoing research and development in this field promise a future where lung cancer is managed with precision and care.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is PD-L1, and why is it important in lung cancer?

PD-L1, or Programmed Death-Ligand 1, is a protein that cancer cells use to avoid being detected and destroyed by the immune system. Specifically, PD-L1 binds to the PD-1 receptor on immune cells, which inhibits the immune cells' ability to attack the cancer. This interaction is significant because blocking it with immunotherapies can allow the immune system to target and eliminate cancer cells. However, not all lung cancer patients respond to these immunotherapies, making PD-L1 testing essential to determine which patients are most likely to benefit. The implications of understanding PD-L1 are far-reaching, enabling tailored treatment plans and improved patient outcomes.

How does PD-L1 testing help in treating lung cancer?

PD-L1 testing measures the amount of PD-L1 protein present on lung cancer cells. This is important because the level of PD-L1 expression can help predict how likely a patient is to respond to immunotherapy. Higher PD-L1 expression often indicates a greater chance of success with immunotherapy treatments. The implication is that doctors can use PD-L1 testing results to determine the most effective treatment strategy for each patient, potentially improving outcomes and reducing unnecessary exposure to treatments that are unlikely to work. This guides treatment decisions to individual patients.

What are cytology specimens, and why are they relevant for PD-L1 testing?

Cytology specimens are samples collected through less invasive methods, such as fine needle aspirations or pleural effusions, instead of traditional biopsies or surgical resections. Using cytology specimens for PD-L1 testing matters because it offers a more convenient and accessible way to assess PD-L1 expression, especially for patients who may not be able to undergo more invasive procedures. It ensures that a broader range of patients can be considered for personalized lung cancer treatment. The implications include expanded access to immunotherapy and potentially improved outcomes for a larger population of lung cancer patients. These samples are more accessible for patients.

Why is it important that PD-L1 testing is accurate and reliable?

The accuracy and reliability of PD-L1 testing are vital because treatment decisions are based on the test results. If PD-L1 testing provides reliable results, doctors can confidently tailor therapies to individual patients. Good agreement between different PD-L1 immunohistochemistry (IHC) kits, such as 28-8 and SP263, ensures consistency in PD-L1 assessment. Excellent interobserver agreement among pathologists is crucial for the reproducibility of PD-L1 testing in clinical practice. The implication is that consistent and accurate PD-L1 testing leads to more effective and personalized lung cancer treatment.

What does personalized lung cancer treatment mean, and why is it important?

Personalized lung cancer treatment involves tailoring therapies to individual patients based on specific characteristics of their cancer, such as the expression of Programmed Death-Ligand 1 (PD-L1). It's important because it allows doctors to select the treatments most likely to be effective for each patient, improving outcomes and reducing unnecessary side effects. The implications of personalized medicine are significant, as it represents a shift towards more precise and effective cancer care, ultimately enhancing the quality of life for those affected by lung cancer. The goal is to ensure that treatments are matched to the unique characteristics of each patient's cancer.